

**BEST AVAILABLE COPY****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****In re Application**

Inventor(s): Gluckman et al.

Appln. No.: 10/606,574

Confirm. No.: 4791

Filed: June 26, 2003

Title: REGULATION OF TYROSINE HYDROXYLASE  
BY GPE**PATENT APPLICATION**

Art Unit: 1654

Examiner: Jeffrey E. Russel

**Customer No. 23910****CERTIFICATE OF OWNERSHIP UNDER 37 C.F.R. §3.73(b)**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

ASSIGNEE, a X corporation    partnership    other (specify), makes this statement to establish ownership of the patent application identified above pursuant to 37 C.F.R. §3.73(b).

The following evidentiary documents establish a chain of title from the original owner to the Assignee:

  X   a copy of an Assignment attached hereto, the original of which has been (or is herewith) forwarded to the Patent and Trademark Office for recording; or  
       the Assignment recorded on        at reel    frames        -       .

The evidentiary documents have been reviewed and Assignee hereby certifies that, to the best of Assignee's knowledge and belief, title to the above-identified patent application is in the Assignee.

If the assignee is owner of less than the entire right title and interest, the ownership interest of the Assignee is identified pursuant to 37 C.F.R. §3.73(c)(2) as follows:       .

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the Assignee.

- 1 -

Attorney Docket No.: NRNZ 1005 LIS1 263.001:060503  
dbb/NRNZ/1005.007.Certificate of Ownership 01/10/05-13:29

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Neuren Pharmaceuticals Ltd.

Date: 10 Jan 2005

By:

Jones

Print Name:

Kathryn Jones

Title:  
2005

Chief Business Officer January 10,

- 2 -

Attorney Docket No.: NRNZ 1005 US1 261.001:050303  
dob/NRNZ/1005.007.Certificate of Ownership 01/10/05-1329

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

PATENT

Inventor(s): Gluckman et al.

Patent No.: 6,187,906

Issued: February 13, 2001

Title: METHODS TO IMPROVE NEURAL OUTCOME**CERTIFICATE OF OWNERSHIP UNDER 37 C.F.R. '3.73(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

ASSIGNEE, a X corporation    partnership    other (specify), makes this statement to establish ownership of the patent application identified above pursuant to 37 C.F.R. '3.73(b).

The following evidentiary documents establish a chain of title from the original owner to the Assignee:

  X   a copy of an Assignment attached hereto, the original of which has been (or is herewith) forwarded to the Patent and Trademark Office for recording; or

       the Assignment recorded on        at reel    frames        -       .

The evidentiary documents have been reviewed and Assignee hereby certifies that, to the best of Assignee's knowledge and belief, title to the above-identified patent application is in the Assignee.

If the assignee is owner of less than the entire right title and interest, the ownership interest of the Assignee is identified pursuant to 37 C.F.R. '3.73(c)(2) as follows:       

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the Assignee.

- 1 -

Attorney Docket No.: NENZ 1002 US2  
dbb/NRHZ/1002 US2.002.CERTIFICATE OF OWNERSHIP 6187906

263.001:050503  
01/11/05-12:16

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Neuren Pharmaceuticals Ltd.

Date: 11 Jan 2005

By: Jones

Print Name: Kathryn Jones

Title: Chief Business Officer

- 2 -

Attorney Docket No.: NRNZ 1002 US2  
dbb/NRNZ/1002 US2.002.CERTIFICATE OF OWNERSHIP 6187906

263.001:050503  
01/11/05-12:36

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Application**

**PATENT**

**Inventor(s):** Gluckman et al.

**Patent No.: 6,812,208**

Issued: November 2, 2004

**Title:** METHODS TO IMPROVE NEURAL OUTCOME

**CERTIFICATE OF OWNERSHIP UNDER 37 C.F.R. § 3.73(b)**

**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Sir,

ASSIGNEE, a X corporation \_\_\_ partnership \_\_\_ other (specify), makes this statement to establish ownership of the patent application identified above pursuant to 37 C.F.R. '3.73(b).

**The following evidentiary documents establish a chain of title from the original owner to the Assignee:**

X a copy of an Assignment attached hereto, the original of which has been (or is herewith) forwarded to the Patent and Trademark Office for recording; or

the Assignment recorded on \_\_\_\_\_ at reel \_\_\_\_\_ frames \_\_\_\_\_ - \_\_\_\_\_

The evidentiary documents have been reviewed and Assignee hereby certifies that, to the best of Assignee's knowledge and belief, title to the above-identified patent application is in the Assignee.

If the assignee is owner of less than the entire right title and interest, the ownership interest of the Assignee is identified pursuant to 37 C.F.R. '3.73(c)(2) as follows: \_\_\_\_\_

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the Assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under '1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Neuren Pharmaceuticals Ltd.

Date: 11 Jan 2005

By: 

Print Name: Kathryn Jones

Title: Chief Business Officer

- 2 -

Attorney Docket No.: NBNZ 1002 US3  
dab/NBNZ/1002 US3.001.CERTIFICATE OF OWNERSHIP 6812208

263.001:050503  
01/11/05-10:53

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

PATENT

Inventor(s): Gluckman et al.

Patent No.: 6,780,848

Issued: August 24, 2004

Title: USE OF GPE TO PROTECT GLIAL CELLS OR  
NON-DOPAMINERGIC CELLS FROM DEATH  
FROM NEURAL INJURY OR DISEASECERTIFICATE OF OWNERSHIP UNDER 37 C.F.R. '3.73(b)Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

ASSIGNEE, a X corporation        partnership        other (specify), makes this statement to establish ownership of the patent application identified above pursuant to 37 C.F.R. '3.73(b).

The following evidentiary documents establish a chain of title from the original owner to the Assignee:

  X   a copy of an Assignment attached hereto, the original of which has been (or is herewith) forwarded to the Patent and Trademark Office for recording; or

       the Assignment recorded on        at reel        frames        -       .

The evidentiary documents have been reviewed and Assignee hereby certifies that, to the best of Assignee's knowledge and belief, title to the above-identified patent application is in the Assignee.

If the assignee is owner of less than the entire right title and interest, the ownership interest of the Assignee is identified pursuant to 37 C.F.R. '3.73(c)(2) as follows:       .

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the Assignee.

- 1 -

Agency Docket No.: NRMZ 1002 US4  
doc/NRMZ/1002 US4.003.CERTIFICATE OF OWNERSHIP 6780848263.001:050503  
01/11/05-10:54

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under \* 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Neuren Pharmaceuticals Ltd.

Date: 11 Jan 2005

By: 

Print Name: Kathryn Jones

Title: Chief Business Officer

- 2 -

Amend. No.: NRNZ 1002 US4  
dbb/NRNZ/1002 US4.008.CERTIFICATE OF OWNERSHIP 6789848

263.001.050603  
01/11/05-10:54



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

PATENT

Inventor(s): Tajrena Alexi

Patent No.: 6,682,753

Issued: January 27, 2004

Title: METHODS FOR PROMOTING WEIGHT GAIN  
USING GPE-RELATED COMPOUNDSCERTIFICATE OF OWNERSHIP UNDER 37 C.F.R. '3.73(b)Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

ASSIGNEE, a X corporation \_\_\_ partnership \_\_\_ other (specify), makes this statement to establish ownership of the patent application identified above pursuant to 37 C.F.R. '3.73(b).

The following evidentiary documents establish a chain of title from the original owner to the Assignee:

X a copy of an Assignment attached hereto, the original of which has been (or is herewith) forwarded to the Patent and Trademark Office for recording; or

\_\_\_ the Assignment recorded on \_\_\_ at reel \_\_\_ frames \_\_\_ - \_\_\_

The evidentiary documents have been reviewed and Assignee hereby certifies that, to the best of Assignee's knowledge and belief, title to the above-identified patent application is in the Assignee.

If the assignee is owner of less than the entire right title and interest, the ownership interest of the Assignee is identified pursuant to 37 C.F.R. '3.73(c)(2) as follows: \_\_\_\_\_

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the Assignee.

- 1 -

Attorney Docket No.: NRNZ 1017 US1  
d/bb/NRNZ/1017.001.CERTIFICATE OF OWNERSHIP 6682753263.001:050503  
01/11/05-10:54

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under \*1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Neuren Pharmaceuticals Ltd.

Date: 11 Jan 2005

By: *K Jones*

Print Name: Kathryn Jones

Title: Chief Business Officer

- 2 -

Attorney Docket No.: NRNZ 1017 US1  
abb/NRNZ/1017.001 CERTIFICATE OF OWNERSHIP 6682753

263.007-050503  
01/11/05-10:54

**CORPORATE TO CORPORATE  
ASSIGNMENT OF PATENTS, APPLICATIONS, AND INVENTIONS**

WHEREAS, NeuronZ Ltd. (hereinafter termed "the Assignor"), a New Zealand company having a place of business at Level 3, 2-6 Park Avenue, Grafton, Auckland, New Zealand, is the owner of all right title and interest in the following patents and patent applications:

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Application No.:	PCT/SE94/00454
Attorney Docket No.:	NRNZ-1001WO

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Application No.:	10/087,011
Attorney Docket No.:	NRNZ-1001US2

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Patent No.:	US 5,804,550
Attorney Docket No.:	NRNZ-1001US0

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Patent No.:	AU 685,123
Attorney Docket No.:	NRNZ-1001AU0

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Application No.:	CA 2,162,924
Attorney Docket No.:	NRNZ-1001CA0

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Patent No.:	EP 697886
Attorney Docket No.:	NRNZ-1001EP0

Title:	New peptide antagonists at glutamate and NMDA receptors
Inventors:	J.P. Bourguignon
Application No.:	JP524705/1994
Attorney Docket No.:	NRNZ-1001JP0

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	1) NZ 250572 2) NZ 260091 3) NZ 264070
Attorney Docket No.:	NRNZ-1002L1,2,3

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	PCT/NZ94/00143
Attorney Docket No.:	NRNZ-1002WO

Title:	Use of tripeptide GPE for treating or preventing symptoms of Parkinson's disease
Inventors:	Gluckman, Williams, Guan, Krishnamurthi
Application No.:	PCT/US02/16809
Attorney Docket No.:	NRNZ-1002WOS

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Patent No.:	AU 700,838
Attorney Docket No.:	NRNZ-1002AU

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	NZ 330,758
Attorney Docket No.:	NRNZ-1002NZ

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	CA 2178711
Attorney Docket No.:	NRNZ-1002CA

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	CN 94195037.9
Attorney Docket No.:	NRNZ-1002CN

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	EP 95904702.8
Attorney Docket No.:	NRNZ-1002EP

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	JP 517338/95
Attorney Docket No.:	NRNZ-1002JP

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	US 08/656,331
Attorney Docket No.:	NRNZ-1002US0

Title:	Compositions and methods to improve neural outcome
Inventors:	Gluckman, Williams
Application No.:	US 08/907,918
Attorney Docket No.:	NRNZ-1002US1

Title:	Methods to improve neural outcome
Inventors:	Gluckman, Williams, Guan
Patent No.:	US 6,187,906
Attorney Docket No.:	NRNZ-1002US2

Title:	Methods to improve neural outcome
Inventors:	Gluckman, Williams, Guan, Krishnamurthi
Application No.:	US 09/866,536
Attorney Docket No.:	NRNZ-1002US3

Title:	Use of GPE to protect glial cells or non-dopaminergic cells from death from neural injury or disease
Inventors:	Gluckman, Williams
Patent No.:	US 6,760,848
Attorney Docket No.:	NRNZ-1002US4

Title:	Composition and methods to improve neural outcome
Inventors:	Gluckman, Kriszsanzen, Kamwar, Strimanne
Application No.:	US 10/119,386
Attorney Docket No.:	NRNZ-1002US5

Title:	Regulation of Neural Enzymes
Inventors:	Gluckman, Williams, Guan
Application No.:	NZ 299511 NZ 299512 NZ299513
Attorney Docket No.:	NRNZ-1003L

Title:	Regulation of Neural Enzymes
Inventors:	Gluckman, Williams, Guan
Application No.:	PCT/NZ97/00132
Attorney Docket No.:	NRNZ-1003WO

Title:	Regulation of Neural Enzymes
Inventors:	Gluckman, Williams, Guan
Patent No:	US 6,365,573
Attorney Docket No.:	NRNZ-1003US0

Title:	Regulation of Neural Enzymes
Inventors:	Gluckman, Williams, Guan
Application No. or Patent No.:	AU 743,412 NZ 335,544 CA 2,267,523 EP 97945106.5 JP 516411/98
Attorney Docket No.:	NRNZ-1003

Title:	Neuronal Rescue Agent
Inventors:	Gluckman, Williams, Wu, Hughes, Lai
Application No.:	US 10/157,542
Attorney Docket No.:	NRNZ-1004US1

Title:	Neuronal Rescue Agent
Inventors:	Gluckman, Williams, Wu, Hughes, Lai
Application No.:	US 09/508,897
Attorney Docket No.:	NRNZ-1004US0

Title:	Receptor
Inventors:	Gluckman, Clark, Sheepens, Tong, Gilmour
Application No.:	NZ 527,027
Attorney Docket No.:	NRNZ-1007

Title:	GPE analogues
Inventors:	Gluckman, Alexi
Application No.:	PCT/US01/41883 US 10/362,266 EP 01968959.5
Attorney Docket No.:	NRNZ-1008

Title:	Functional proteomics using double phage display screening
Inventors:	Gilmour, Marvin
Application No.:	PCT/US01/47838 US 10/433,738
Attorney Docket No.:	NRNZ-1009

Title:	Compositions and methods for the rescue of white matter
Inventors:	Guan, Gunn, Bennet, Egan
Application No.:	PCT/US01/47749 US 60/254,349 US 60/287,688 US 10/013,812
Attorney Docket No.:	NRNZ-1010

Title:	Regulation of weight
Inventors:	Alexi
Application or Patent No.:	US 60/278,562 PCT/US02/07886 EP 02726620.4 US Patent No: 6,682,753
Attorney Docket No.:	NRNZ-1017



Title:	Neuronal Rescue Agent
Inventors:	Gluckman, Williams, Wu, Hughes, Lai
Application No.:	PCT/NZ98/00139
Attorney Docket No.:	NRNZ-1004WO

Title:	Neuronal Rescue Agent
Inventors:	Gluckman, Williams, Wu, Hughes, Lai
Patent No.:	AU 738,192
Attorney Docket No.:	NRNZ-1004AU

Title:	Regulation of tyrosine hydroxylase
Inventors:	Gluckman, Guan, Alexi
Application No. or Patent No.:	PCT/NZ99/00085 AU 751,217 CN 99807332.6 EP 99928258.5 JP 554388/2000 NZ 330,684 US Pat. No. 6,617,311 US Application No. 10/606,574
Attorney Docket No.:	NRNZ-1005

Title:	Neuroprotection
Inventors:	Scheepens, Williams, Gluckman, Clark
Application No. or Patent No.:	PCT/NZ99/00147 AU 757,907 CN 99810613.5 EP 99 846 457.1 BR 1991/13457-8 JP 568459/2000 NZ 510,253 US 09/786,962
Attorney Docket No.:	NRNZ-1006

Title:	GPE analogs and peptidomimetics
Inventors:	Abood, Brimble
Application No.:	PCT/US02/16361
Attorney Docket No.:	NRNZ-1018WO

Title:	GPE analogs and peptidomimetics
Inventors:	Abood, Brimble
Application No.:	JP 2002-592330
Attorney Docket No.:	NRNZ-1018JP0

Title:	GPE analogs and peptidomimetics
Inventors:	Abood, Brimble
Application No.:	EP 02731918.5
Attorney Docket No.:	NRNZ-1018EP0

Title:	GPE analogs and peptidomimetics
Inventors:	Abood, Brimble
Application No.:	US 10/155,684
Attorney Docket No.:	NRNZ-1018US1

Title:	Neuroprotection and /or neurorestoration via the neural activin type IIB receptor
Inventors:	Hughes, Fernandez, Raniga
Application No.:	PCT/US02/20111 US 60/300,514 US 10/177,735
Attorney Docket No.:	NRNZ-1019

Title:	Neuronal Restoration Agents
Inventors:	Wu, Williams
Application No.:	US 60/371,861
Attorney Docket No.:	NRNZ-1021

Title:	Compositions and methods for the treatment of brain damage
Inventors:	Sieg, Hughes
Application No.:	US 60/314,952 PCT/US02/26782
Attorney Docket No.:	NRNZ-1023

Title:	Neural Regeneration peptides and Methods for their Use in Treatment of Brain damage
Inventors:	Sieg, Hughes
Application No.:	US 10/225,838
Attorney Docket No.:	NRNZ-1023US1

Title:	Neural Regeneration Peptides and Methods for their Use in Treatment of Brain damage
Inventors:	Sieg, Gorba
Application No.:	US 60/515,018
Attorney Docket No.:	NRNZ-1023US3

Title:	Neural Regeneration peptides and Methods for their Use in Treatment of Brain damage
Inventors:	Sieg, Gorba
Application No.:	US 60/585,041
Attorney Docket No.:	NRNZ-1023US4

Title:	Treatment on demyelinating diseases
Inventors:	Krissansen, Kanwar
Application No.:	NZ 507,478 PCT/US01/32187 EP01981601.6
Attorney Docket No.:	NRNZ-1033

Title:	Treatment on demyelinating diseases
Inventors:	Krissansen, Kanwar
Application No.:	NZ 507,478 PCT/US01/32198 US 10/398,876
Attorney Docket No.:	NRNZ-1034

Title:	Cyclo(propyl-glycine) and methods of use to treat neural disorders
Inventors:	Guan, Gluckman, Thomas, Sleg
Application No.:	NZ 515,371 NZ 515,432 NZ 515,551 PCT/US2002/038235
Attorney Docket No.:	NRNZ-1038

Title:	Compositions and methods for immunomodulation
Inventors:	Gluckman
Application No.:	PCT/US03/08714 US 60/370,768
Attorney Docket No.:	NRNZ-1038

Title:	Treatment of diabetes
Inventors:	Vickers
Application No.:	US 60/527,024
Attorney Docket No.:	NRNZ-1043

Title:	Compositions and Methods For the Treatment of Degenerative Diseases And Conditions of The Body
Inventors:	Gluckman, Egan
Application No.:	US 60/397,827 US 60/489,167
Attorney Docket No.:	NRNZ-1044

Title:	Use of Gly-Pro-Glu to Treat Spinal Cord and Peripheral Nerve Damage
Inventors:	Gluckman, Williams, Clarke, Srimanne
Application No.:	US 60/538,577
Attorney Docket No.:	NRNZ-1046

Title:	Cyclic Proline-Containing Peptide Mimetics
Inventors:	Harris, Brimble
Application No.:	US 60/456,138 US 60/505,119 PCT/US04/008108
Attorney Docket No.:	NRNZ-1048

Title:	NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE
Inventors:	Brimble, Guan, Sieg
Application No.:	PCT/US04/28308
Attorney Docket No.:	NRNZ-1050

Title:	Neuroprotective Effects of Gly-Pro-Glu Following Intravenous Infusion
Inventors:	Guan, Thomas, Batchelor, Breier, Gluckman
Application No.:	US 60/553,688
Attorney Docket No.:	NRNZ-1052US2

Title:	Pharmacokinetics of GPE and methods of its administration
Inventors:	Batchelor, Thomas, Breier, Gluckman
Application No.:	US 60/515,397
Attorney Docket No.:	NRNZ-1052US1

Title:	Anti-GPE antibodies, their uses and analytical methods for GPE
Inventors:	Thomas, Breier, Batchelor
Application No.:	PCT/US02/08195
Attorney Docket No.:	NRNZ-1016WO0

Title:	Anti-GPE antibodies, their uses and analytical methods for GPE
Inventors:	Thomas, Breier, Batchelor
Application No.:	EP 02753654.9
Attorney Docket No.:	NRNZ-1016EP0

Title:	Anti-GPE antibodies, their uses and analytical methods for GPE
Inventors:	Thomas, Breier, Batchelor
Application No.:	US 10/100,515
Attorney Docket No.:	NRNZ-1016US1

Title:	GPE and GPE analogues /peptidomimetics and caffeineol improve sensory-motor function recovery after stroke in rats
Inventors:	Grotta, Gluckman
Application No.:	US 60/557,940
Attorney Docket No.:	NRNZ-1053US0

Title:	GPE and G2MePE in combination with caffeineol improve sensory motor function recovery after stroke
Inventors:	Grotta, Gluckman
Application No.:	US 60/572,627
Attorney Docket No.:	NRNZ-1053US1

WHEREAS, PATENT PROPERTY shall include each and all of the following:

(a) each of the foregoing patents and patent applications therefor and all documents from which any of the above patents and patent applications claim priority and the inventions disclosed therein, and all embodiments of such inventions heretofore assigned to ASSIGNOR [all collectively hereinafter termed "Inventions"];

(b) all rights to apply in any and all countries of the world for patents, certificates of invention or other governmental grants on said inventions, including the right to apply for patents pursuant to the International Convention for the Protection of Industrial Property or pursuant to any other convention, treaty, agreement or understanding;

(c) any and all applications filed and any and all patents, certificates of invention or other governmental grants granted on said inventions in each and every country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications;

(d) each and every reissue or extension of any of said patents;

(e) each and every patent claim resulting from a reexamination certificate for any and all of said patents, and

(f) the right to sue for and all claims for damages, profits or other recovery resulting from infringement, including past infringement, of any of the foregoing.

WHEREAS Neuren Pharmaceuticals Ltd. (hereinafter termed "Assignee"), a New Zealand company having a place of business at Level 3, 2-6 Park Avenue, Grafton, Auckland, Country of New Zealand, is to acquire from ASSIGNOR the entire rights, title and interest in and to said Patent Property.


NOW THEREFORE, for good and valuable consideration acknowledged by said ASSIGNOR to have been received in full from said ASSIGNEE:

1. ASSIGNOR hereby sells, assigns, transfers and otherwise conveys to ASSIGNEE, and ASSIGNEE's successors, legal representatives and assigns, the entire right, title, and interest in and to the PATENT PROPERTY.

2. ASSIGNOR further agrees to execute and cause to be executed such additional instruments as may be necessary or desirable to confirm the transfer of rights as herein contemplated, to record the transfer of rights in the United States and throughout the world, and to permit ASSIGNEE, and ASSIGNEE's successors, legal representatives and assigns to enforce the PATENT PROPERTY.

IN WITNESS WHEREOF, EXHIBITION has caused this document to be executed by its duly authorized officer and assigned to ASSIGNEE this 1<sup>st</sup> day of January, 2004 at the County of New Zealand  
 The ASSIGNMENT may be executed in counterparts. If this ASSIGNMENT is executed in counterparts, all counterparts together shall be deemed to be a single instrument.

Newport Ltd.

By:   
 (Signature)  
 Name: Robert Conner

Title: Director

Signature Date: 12.10.04


By: \_\_\_\_\_  
 (Signature)

Name: Jim McLean

Title: Director

Signature Date: \_\_\_\_\_

Witness:

By:   
 (Signature)  
 Name: Gabrielle Peters  
 Signature Date: 12.10.04

By: \_\_\_\_\_  
 (Signature)

Name: \_\_\_\_\_

Signature Date: \_\_\_\_\_



IN WITNESS WHEREOF, ASSIGNOR has caused this instrument to be executed by its duly authorized corporate officer and delivered to ASSIGNEE this 1<sup>st</sup> day of January, 2004 in the Country of New Zealand.

This ASSIGNMENT may be executed in counterparts. If this ASSIGNMENT is executed in counterparts, all counterparts together shall be considered to be a single instrument.

NeuronZ Ltd.

By: \_\_\_\_\_  
(Signature)

Name: Robin Congreve

Title: Director

Signature Date: \_\_\_\_\_

By: [Signature]  
(Signature)

Name: Jim McLay

Title: Director

Signature Date: 15/10/04

Witnesses:

By: \_\_\_\_\_  
(Signature)

Name: \_\_\_\_\_

Signature Date: \_\_\_\_\_

By: [Signature]  
(Signature)

Name: SANDY SCHADE

Signature Date: 15/10/04

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**